4 Results for "

SNU475

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "SNU475" in MCE Product Catalog:

Cat. No.: HY-156397
Purity:  99.42%
Target:  

AMPK YAP

Research Areas:  

Cancer

HTH-02-006 is a NUAK2 inhibitor, with an IC50 value of 126 nM. HTH-02-006 inhibits NUAK2-mediated signaling by reducing phosphorylation of its substrate MYPT1 at S445 and downstream MLC. HTH-02-006 shows growth inhibitory efficacy in YAP-high cancer cells (HuCCT-1, SNU475). HTH-02-006 significantly suppresses YAP-induced hepatomegaly (reduced liver/body weight ratio) in TetO-YAP S127A transgenic mice and demonstrates significant anti-tumor efficacy in mice bearing HMVP2 prostate cancer allografts. HTH-02-006 can be used for the study of liver cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-161648
Target:  

Drug Derivative

Research Areas:  

Cancer

Anticancer agent 222 (Compound 19) is an orally active anticancer agent that exhibits significant anticancer activity against Huh7, FOCUS, SNU475, SNU182, HepG2, and Hep3B cells (IC50 = 2.9–9.3 μM) .
loading...
    loading...
Cat. No.: HY-164467
CAS No.: 485319-41-3
Target:  

Wnt

Research Areas:  

Cancer

CCT070535 blocks TCF-dependent transcription at the TCF level, with GI50 values of 17.6 μM, 11.1 μM, 11.8 μM and 13.4 μM in HT29 (APC mutant), HCT116 (oncogenic β-catenin), SW480 (APC mutant) and SNU475 (Axin mutant) cells, respectively .
loading...
    loading...
Cat. No.: HY-184592
Target:  

JAK STAT Akt PARP Caspase

Research Areas:  

Cancer

JAK1-IN-21, biotin-conjugated isoxazole derivative, is a JAK1 inhibitor. JAK1-IN-21 directly engages and stabilizes JAK1, reduces the phosphorylation of JAK1, STAT1 and AKT, induces apoptotic marker cleavage (PARP, Caspase-3, Caspase-7) and exhibits broad-spectrum antiproliferative activity against cancer cells. JAK1-IN-21 can be used for the study of liver cancer, prostate cancer, and breast cancer .
loading...
    loading...